tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Summit Therapeutics reports Q2 non-GAAP EPS (12c) , consensus (7c)

Aggregate cash and cash equivalents and short-term investments were $297.9M and $412.3M at June 30, 2025 and December 31, 2024, respectively.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1